World’s Largest Dental Research Meeting to Be Held in Yokohama in 2029
10.9.2025 18:00:00 EEST | Business Wire | Press release
The 2029 International Association for Dental, Oral, and Craniofacial Research (IADR) General Session & Exhibition will be held in Yokohama from June 27 to June 30, 2029, marking the return of the event to Japan after 28 years. The IADR General Session is held in conjunction with the IADR Asia Pacific Regional (APR) Meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910478673/en/
YOKOHAMA JAPAN'S FIRST PORT OF CALL
Working in partnership with the City of Yokohama and the Japan National Tourism Organization (JNTO), the Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama have secured the bid to host the 2029 IADR General Session—owing to Yokohama’s convenient access, excellent reputation in hosting international conferences, and robust support infrastructure. The decision was also based on the extensive legacy of world-leading dental, oral, and craniofacial research in Japan, and the long-standing activities of the Japanese Association for Dental Research (JADR).
Comment from Professor Satoshi Imazato, IADR Immediate Past President
“I am delighted that Yokohama has been selected to host the IADR General Session. IADR is the world’s largest dental, oral, and craniofacial research organization, and its Japanese Division has long had the second-largest membership, after that of the United States. As the fourth Japanese president of the IADR, a position I held until June of 2025, I am particularly proud that the IADR General Session will be held in Yokohama—a cosmopolitan city with wide international access. I hope to lead a successful conference in Yokohama while also strengthening the spirit of collaboration between Japan and the global research community, further enhancing the international status of Japanese dental researchers.”
Event Details
Name: IADR/APR General Session & Exhibition
Dates: Wednesday, June 27, to Saturday, June 30, 2029
Venue: PACIFICO Yokohama
Expected Attendance: 5,000 on-site participants (including approximately 4,750 from outside Japan)
Organizer: International Association for Dental, Oral, and Craniofacial Research (IADR) https://www.iadr.org/
The event will bring together a diverse range of participants in Yokohama, including researchers, industry leaders, and clinicians from across the global dental, oral, and craniofacial research community. The accompanying exhibition will feature the latest technologies, hands-on demonstrations, and opportunities for meaningful business exchange.
About the Yokohama City Visitors Bureau
The role of the Yokohama City Visitors Bureau (YCVB) is to employ the wealth of resources existing in the City of Yokohama and Kanagawa Prefecture to promote the region as an ideal destination for both tourists and international conventions. In this way, the YCVB is contributing to the reinvigoration of the City of Yokohama and surrounding areas, and the advancement of its globalization.
About IADR
The International Association for Dental, Oral, and Craniofacial Research (IADR) is a nonprofit organization with a mission to drive dental, oral, and craniofacial research for health and well-being worldwide. IADR represents the individual scientists, clinician-scientists, dental professionals, and students based in academic, government, non-profit, and private-sector institutions who share our mission. Learn more at www.iadr.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910478673/en/
Contacts
Yuki Hori
Manager, Business Events Team
Yokohama City Visitors Bureau
Email: mice@ycvb.or.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom